In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...
Susan M. Love, MD, MBA, a renowned surgeon, author, researcher, and patient advocate who dedicated her life’s work to breast cancer care, died on July 2, 2023, at her home in Los Angeles. The cause of death was recurrent leukemia. She was 75. Born in Long Branch, New Jersey, on February 9, 1948,...
In a Canadian study reported in the Journal of Clinical Oncology, Dayes et al found that positron-emission tomography/computed tomography–fluorodeoxyglucose (PET/CT-FDG) improved the detection of distant metastasis vs conventional staging in patients with locally advanced breast cancer. It also...
Sarah Cannon Research Institute (SCRI) recently announced that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah will oversee SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the...
On November 15, 2023, repotrectinib (Augtyro) was approved for locally advanced or metastatic ROS1 fusion–positive non–small cell lung cancer (NSCLC).1 This is the first U.S. Food and Drug Administration approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1...
It is currently acknowledged that hypofractionated radiotherapy, an increasingly favored approach in prostate cancer treatment, delivers higher radiation doses over fewer sessions compared with conventional fractionation schedules. This approach is supported by the recognition that prostate...
For patients with gastric MALT (mucosa-associated lymphoid tissue) lymphoma, an “ultra-low dose” of radiotherapy was as effective as the higher, standard dose in providing local control and freedom from distant relapse, researchers from The University of Texas MD Anderson Cancer Center reported at...
Investigators have found that annual breast cancer screening beginning at age 40 and continuing to at least 79 may result in the greatest reduction in mortality with minimal risks, according to a recent study published by Monticciolo et al in Radiology. Background Breast cancer is the second most ...